Sol-Gel Technologies Ltd. SLGL
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.19
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $11.5M | $1.6M | $3.9M | $31.3M | $8.7M | $22.8M | $129.0K | $174.0K | — |
| R&D | $22.8M | $17.8M | $23.5M | $12.7M | $20.4M | $27.9M | $40.6M | $28.1M | $25.8M | $17.0M |
| SG&A | $4.2M | $5.7M | $7.4M | $7.4M | $8.5M | $11.1M | $8.3M | $5.5M | $6.0M | $3.7M |
| Operating income | -$7.5M | -$12.0M | -$29.3M | -$16.2M | $3.0M | -$30.2M | -$25.9M | -$33.5M | -$31.6M | -$20.8M |
| Pre-tax income | -$6.1M | -$10.6M | -$27.2M | — | $3.2M | -$29.3M | -$24.6M | -$32.2M | -$31.6M | — |
| Income tax | $0 | $0 | $0 | — | $0 | $0 | $33.0K | — | — | — |
| Net income | -$6.1M | -$10.6M | -$27.2M | -$14.9M | $3.2M | -$29.3M | -$24.6M | -$32.2M | -$31.6M | -$20.8M |
| EPS, basic | -2.19 | -3.79 | -10.01 | -0.65 | 0.14 | -1.30 | -1.26 | — | — | — |
| EPS, diluted | -2.19 | -3.79 | -10.01 | -0.65 | 0.14 | -1.30 | -1.26 | 1.80 | 5.02 | 3.30 |
| Shares, diluted (wtd. avg.) | 2.8M | 2.8M | 2.7M | 23.1M | 23.6M | 22.6M | 19.5M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.0M | $19.5M | $7.5M | $13.6M | $21.2M | $8.3M | $9.8M | $5.7M | $5.0M | $7.0M |
| Short-term investments | $13.0M | $4.4M | $20.5M | $8.7M | $1.7M | $21.7M | $41.0M | $56.7M | — | — |
| Receivables | $2.0M | $3.6M | $377.0K | $62.0K | $13.1M | $2.2M | $4.1M | — | — | — |
| Total current assets | $27.0M | $31.3M | $41.2M | $43.1M | $57.1M | $53.4M | $55.8M | $66.0M | $10.5M | $8.3M |
| Property, plant and equipment | $140.0K | $202.0K | $434.0K | $660.0K | $1.1M | $1.8M | $2.3M | $2.6M | $2.3M | $798.0K |
| Total assets | $29.9M | $35.8M | $45.3M | $46.6M | $69.2M | $59.2M | $61.3M | $69.7M | $15.3M | $11.0M |
| Accounts payable | — | — | — | — | $766.0K | $1.2M | $1.7M | $2.9M | $534.0K | $667.0K |
| Short-term debt | — | — | — | — | — | — | — | — | $65.3M | $37.3M |
| Total current liabilities | $6.2M | $5.3M | $4.5M | $3.3M | $11.7M | $6.0M | $6.5M | $4.9M | $67.2M | $41.6M |
| Total liabilities | $7.1M | $7.0M | $6.6M | $4.4M | $13.6M | $8.3M | $8.8M | $5.8M | $68.0M | $42.3M |
| Retained earnings | -$237.0M | -$230.9M | -$220.3M | -$193.1M | -$178.1M | -$181.4M | -$152.1M | -$127.5M | -$95.3M | -$63.7M |
| Total equity | $22.8M | $28.9M | $38.6M | $42.2M | $55.6M | $50.8M | $52.5M | $63.9M | -$52.7M | -$31.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $322.0K | -$13.9M | -$17.7M | -$9.5M | -$7.7M | -$25.2M | -$22.5M | -$23.5M | -$24.1M | -$18.5M |
| Depreciation and amortisation | $109.0K | $233.0K | $342.0K | $562.0K | $880.0K | $946.0K | $887.0K | $762.0K | $471.0K | $359.0K |
| Stock-based compensation | $82.0K | $786.0K | $1.9M | $1.5M | $687.0K | $1.2M | $2.6M | $4.7M | $4.0M | $952.0K |
| Capital expenditure | $47.0K | $2.0K | $134.0K | $171.0K | $143.0K | $449.0K | $597.0K | $1.1M | $1.9M | $385.0K |
| Investing cash flow | -$8.6M | $26.7M | -$9.7M | $1.7M | $19.9M | -$2.7M | $16.0M | -$54.7M | -$5.9M | -$391.0K |
| Financing cash flow | $6.0K | $0 | $21.8M | $15.0K | $837.0K | $26.5M | $10.6M | $78.8M | $28.0M | $20.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-001552.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $174.0K | $129.0K | $22.8M | $8.7M | $31.3M | $3.9M | $1.6M | $11.5M | $3.8M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$20.8M | -$31.6M | -$32.2M | -$24.6M | -$29.3M | $3.2M | -$14.9M | -$27.2M | -$10.6M | -$6.1M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |